Total embolization of the main splenic artery as a supplemental treatment modality for hypersplenism
Total embolization of the main splenic artery as a supplemental treatment modality for hypersplenism
复制标题
DOI：
10.3748/wjg.v17.i24.2953
复制
发表时间：
2011-06-28
影响因子：
4.3
通讯作者：
Xu, Li-Chao
中科院分区：
文献类型：
--
作者：
He, Xin-Hong;Li, Wen-Tao;Xu, Li-Chao
目的：目的探讨脾动脉主干栓塞术作为肝硬化合并血小板减少或白细胞减少的脾功能亢进的辅助治疗方法的安全性和可行性。方法：选取2006年1月至2010年6月收治的15例肝硬化脾功能亢进患者。所有患者均行脾动脉主干全栓塞术。记录患者临床症状、白色细胞（WBC）和血小板（PLT）计数、脾脏体积及并发症。结果：脾动脉主干栓塞术全部成功，术后随访1、6个月，1、2、3年。术后1、6、1、2、3年WBC、PLT计数较术前明显升高，残脾体积较术前明显减少（P < 0.01）。此外，残余脾脏体积随栓塞后时间增加非常缓慢。所有患者在随访期间均存活。结论：脾动脉主干全栓塞术是一种安全可行的手术方法，可作为脾功能亢进伴血小板减少或白细胞减少伴肝硬化的补充治疗方式。(C)2011年百世登。All rights reserved.
AIM: To study the safety and feasibility of total embolization of the main splenic artery as a supplemental treatment modality for hypersplenism with thrombocytopenia or leukocytopenia accompanying liver cirrhosis.METHODS: Fifteen consecutive patients with hypersplenism due to cirrhosis were enrolled in this study from January 2006 to June 2010. All patients underwent total embolization of the main splenic artery. Clinical symptoms, white blood cell (WBC) and platelet (PLT) counts, splenic volume, and complications of the patients were recorded. The patients were followed up for 1 and 6 mo, and 1, 2, 3 years, respectively, after operation.RESULTS: Total embolization of the main splenic artery was technically successful in all patients. Minor complications occurred in 13 patients after the procedure, but no major complications were found. The WBC and PLT counts were significantly higher and the residual splenic volume was significantly lower 1 and 6 mo, and 1, 2, 3 years after the procedure than before the procedure (P < 0.01). Moreover, the residual splenic volume increased very slowly with the time after embolization. All patients were alive during the follow-up period.CONCLUSION: Total embolization of the main splenic artery is a safe and feasible procedure and may serve as a supplemental treatment modality for hypersplenism with thrombocytopenia or leukocytopenia accompanying liver cirrhosis. (C) 2011 Baishideng. All rights reserved.